carboplatin,durvalumab,paclitaxel,olaparib,bevacizumab
astrazeneca,merck,roche
['duo-o', '$azn']
$azn #asco23 duo-o late-breaker presentation starting now. here's my story, published earlier today 
Once had a blue tick. Journalist at Evaluate Vantage. Interested in: oncology, immunology. Not interested in: what stock you bought today.